Responses
Poster Presentation
A Phase I, open-label, dose escalation study of MGA271 in combination with pembrolizumab in patients with B7-H3-expressing melanoma, squamous cell cancer of the head and neck, or squamous cell non-small cell lung cancer
Compose a Response to This Article
Other responses
No responses have been published for this article.
